Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications

• DOI: 10.1186/s12967-015-0611-0
• Publication Date: 2015-07-24T03:53:35Z
• Authors: Sureewan Bumrungthai; Kavita Munjal; Shirish Nandekar; Kumarasen Cooper; Tipaya Ekalaksananan; Chamsai Pientong; Mark Francis Evans
• Keywords: PTEN; Epidemiology; DNA Mutational Analysis; Advancements in Lung Cancer Research; Signal transduction; Gene; Cohort Studies; Phosphatidylinositol 3-Kinases; 0302 clinical medicine; Phosphorylation; Extracellular Signal-Regulated MAP Kinases; Internal medicine; Cancer; Medicine(all); Aged, 80 and over; Middle Aged; Immunohistochemistry; 3. Good health; ErbB Receptors; Gene Expression Regulation, Neoplastic; Oncology; Carcinoma, Squamous Cell; PI3K/AKT/mTOR pathway; Medicine; Female; EGFR Mutations; Adult; Pulmonary and Respiratory Medicine; Class I Phosphatidylinositol 3-Kinases; Human Papillomavirus and Cervical Cancer Epidemiology; Exon; Cancer research; 03 medical and health sciences; Health Sciences; Biomarkers, Tumor; KRAS; Genetics; Humans; Biology; Aged; Biochemistry, Genetics and Molecular Biology(all); Epidermal growth factor receptor; Research; Gene Expression Profiling; PTEN Phosphohydrolase; Treatment and Management of Anal Cancer; Colorectal cancer; FOS: Biological sciences; Mutation; Surgery

Cervical squamous cell carcinoma (CSCC) is a major cause of female mortality worldwide. This study has examined epidermal growth factor receptor (EGFR) pathway markers that represent actionable pharmacological targets. HPV16 positive CSCCs (n = 105 patients) from Madhya Pradesh, India were screened for KRAS and PIK3CA mutations by PNA-clamp real-time PCR. Immunohistochemistry (IHC) was performed EGFR, PIK3CA, PTEN, phospho-AKT, phospho-mTOR phospho-44/42 MAPK (ERK1/2). detected in 0/91 (0%) 19/95 (20.0%) informative specimens: exon 9, E542 3) E545 15); 20, H1047R 1). mutation detection associated with older mean patient age [48.2 vs. 56.6 years (P 0.007)] post-menopausal age: 5/45 (11.1%) patients <50 14/50 (28.0%) ≥50 0.045; OR 3.11). EGFR expression present 60/101 (59.4%) < 0.05) but not > 0.05). phospho-AKT staining showed associations tumor grade and/or lymph node status Significant found the other These data show acquisition related to expression. The absence supports potential anti-EGFR therapies CSCC treatment. relatively high rates indicate PI3K may be therapeutic target significant subset patients. Qualitatively distinct IHC profiles marker panel noted patient; however, across patients, consistent linear relationships between up- downstream observed. Evaluation cancer targets value addition molecular profiling choosing among options.